Directed <i>ortho</i>-Lithiation: Observation of an Unexpected 1-Lithio to 3-Lithio Conversion of 1-Lithio-naphthyllithium Compounds with an <i>ortho</i>-Directing 2-(Dimethylamino)methyl Group
作者:Johann T. B. H. Jastrzebski、Anne M. Arink、Henk Kleijn、Thijs W. Braam、Martin Lutz、Anthony L. Spek、Gerard van Koten
DOI:10.1021/ja402884y
日期:2013.9.11
[2-(Me2NCH2)C10H6Li-1]2·L (coordinated L = Et2O: 2b, dman: 2c) in apolar solvents. Heating solutions of 2c in toluene-d8 (to 90 °C) induced a surprisingly clean and quantitative 1-lithio to 3-lithio conversion of the 1-lithio-naphthalene isomer. This type of reaction is rare in organolithium chemistry and has obvious significant implications for the design of regioselective DoL protocols; this thus represents
Carbon–hydrogen and C–X (X = Cl or SiMe<sub>3</sub>) bond activation. 1-Cyclopalladation and oxidation of some derivatives of 2-[(dimethylamino)methyl]naphthalene
作者:Jean-Marc Valk、Ruud van Belzen、Jaap Boersma、Anthony L. Spek、Gerard van Koten
DOI:10.1039/dt9940002293
日期:——
1-bromo-2-[(dimethylamino)methyl]naphthalene to [Pd(dba)2](dba = dibenzylideneacetone). Protection of C(3) with R = SiMe3 resulted in quantitative replacement of the SiMe3 group by palladium. Silicon–oxygen bond cleavage was observed when the substrate with R = OSiMe3 was treated with Pd(O2CMe)2. Palladium bis3-[(dimethylamino)methyl]-2-naphtholate} was obtained quantitatively. Oxidation of several arylpalladium complexes
Lithiations of .alpha.- and .beta.-(dimethylaminomethyl)naphthalenes with n-butyllithium and condensations with benzophenone. Some related results
作者:Robert L. Gay、Charles R. Hauser
DOI:10.1021/ja00986a010
日期:1967.5
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
申请人:[en]NOVARTIS AG
公开号:WO2023214325A1
公开(公告)日:2023-11-09
The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.